The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
 
Andrea Grace Bocobo
No Relationships to Disclose
 
Renee Wang
No Relationships to Disclose
 
Spencer Behr
Consulting or Advisory Role - Advanced Accelerator Applications; GenVivo; More Health; Progenics
Research Funding - Cancer Targeted Technology
 
Julia C. Carnevale
No Relationships to Disclose
 
Pelin Cinar
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma
 
Eric Andrew Collisson
Stock and Other Ownership Interests - BloodQ; Clara Health; Guardant Health; HDT Bio; Hint Health; IHP Therapeutics; One Medical; Tatara Therapeutics; Valar Labs
Research Funding - AstraZeneca (Inst); Ferro Oncology/Bridge Bio (Inst); Loxo/Bayer (Inst); Merck KGaA (Inst)
Expert Testimony - NantBioScience
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; SOTERIA Precision Medicine; Sutro Biopharma
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Innovent Biologics; Janssen Oncology; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Bridget P Keenan
Employment - Astellas Pharma (I)
Research Funding - Partner Therapeutics (Inst)
 
Wesley Allen Kidder
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Medscape; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Kanti Pallav Kolli
Stock and Other Ownership Interests - Adient Medical; Atia medical
Consulting or Advisory Role - OncoSec
 
Megan Kennedy
No Relationships to Disclose
 
Angela Laffan
No Relationships to Disclose
 
Sorbarikor Piawah
No Relationships to Disclose
 
Marin Pollak
No Relationships to Disclose
 
Gabriel Schwartz
Stock and Other Ownership Interests - Sutro Biopharma
Consulting or Advisory Role - Eisai; Exelixis
Speakers' Bureau - Eisai; Incyte
Other Relationship - Exelixis
 
Julia Whitman
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Raydiant Oximetry
Travel, Accommodations, Expenses - Dendreon
 
Katherine Van Loon
Speakers' Bureau - Amgen; Physicans' Education Resource
Research Funding - Celgene (Inst)
 
Chloe Evelyn Atreya
Stock and Other Ownership Interests - Pionyr
Consulting or Advisory Role - Array BioPharma; Inivata; Pfizer; Pionyr
Research Funding - Bristol-Myers Squibb (Inst); Gossamer Bio (Inst); Guardant Health (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Roche